Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi, F Pan, H Liu… - Regulatory Toxicology …, 2022 - Elsevier
Purpose Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy
model (PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic …
model (PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic …
Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi… - Regulatory …, 2022 - pubmed.ncbi.nlm.nih.gov
Purpose Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy
model (PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic …
model (PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic …
Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi, F Pan, H Liu… - Authorea …, 2024 - techrxiv.org
Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy model
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi, F Pan, H Liu, S Yu… - authorea.com
Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy model
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi, F Pan, H Liu, S Yu… - essopenarchive.org
Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy model
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi, F Pan… - Authorea …, 2024 - advance.sagepub.com
Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy model
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi, F Pan… - Regulatory …, 2022 - europepmc.org
Purpose Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy
model (PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic …
model (PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic …
Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients …
Z Wang, W Liu, X Li, H Chen, D Qi, F Pan, H Liu, S Yu… - 2024 - europepmc.org
Our aim is to build a physiologically based pharmacokinetic and JAK2 occupancy model
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …
(PBPK-JO) to simultaneously predict pharmacokinetic (PK) and pharmacodynamic (PD) …